
On Monday, Spanish dermatology group Almirall has released its full-year report for 2021. The headliner has been sales of psoriasis drug Ilumetri, an anti-IL-23 monoclonal antibody treatments for adults that was launched around a year ago. Ilumetri sales reached EUR 82m in 2021, corresponding to a growth of 87 percent, according to the report.
Other takeaways include a good sales performances from Almirall’s acne treatment Seysara and Klisyri, a treatment for the dermatological disease known as actinic keratosis (AK), which was approved in the US in 2020 and in Europe in the second half of 2021.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app